tetano
Editor, Senior Moderator
Mult Scler
. 2024 Jan 21:13524585231218149.
doi: 10.1177/13524585231218149. Online ahead of print. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
Lina Jeantin[SUP] 1 [/SUP], Edouard Januel[SUP] 2 [/SUP], Pierre Labauge[SUP] 3 [/SUP], Elisabeth Maillart[SUP] 1 [/SUP], Jérôme de Seze[SUP] 4 [/SUP], Hélène Zéphir[SUP] 5 [/SUP], Jean Pelletier[SUP] 6 [/SUP], Philippe Kerschen[SUP] 7 [/SUP], Damien Biotti[SUP] 8 [/SUP], Olivier Heinzlef[SUP] 9 [/SUP], Laurent Guilloton[SUP] 10 [/SUP], Caroline Bensa[SUP] 11 [/SUP], Marie Théaudin[SUP] 12 [/SUP], Sandra Vukusic[SUP] 13 [/SUP], Olivier Casez[SUP] 14 [/SUP], Aude Maurousset[SUP] 15 [/SUP], David Laplaud[SUP] 16 [/SUP], Eric Berger[SUP] 17 [/SUP], Christine Lebrun-Frenay[SUP] 18 [/SUP], Bertrand Bourre[SUP] 19 [/SUP], Pierre Branger[SUP] 20 [/SUP], Bruno Stankoff[SUP] 21 [/SUP], Pierre Clavelou[SUP] 22 [/SUP], Eric Thouvenot[SUP] 23 [/SUP], Eric Manchon[SUP] 24 [/SUP], Thibault Moreau[SUP] 25 [/SUP], François Sellal[SUP] 26 [/SUP], Mickaël Zedet[SUP] 27 [/SUP], Caroline Papeix[SUP] 11 [/SUP], Céline Louapre[SUP] 1 [/SUP]
Affiliations
Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021.
Objectives: We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022.
Methods: This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity.
Results: Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave (p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25-1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51-2.67]), obesity (OR = 2.36, 95% CI = [1.52-3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46-3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43-3.06] for EDSS 3-5.5 and OR = 4.53, 95% CI = [3.04-6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85-3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60-0.69]) or off (RR = 0.32, 95% CI = [0.30-0.33]) anti-CD20.
Discussion: In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.
Keywords: COVID-19; COVID-19 testing; COVID-19 vaccines; Multiple sclerosis; SARS-CoV-2; vaccination.
. 2024 Jan 21:13524585231218149.
doi: 10.1177/13524585231218149. Online ahead of print. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022
Lina Jeantin[SUP] 1 [/SUP], Edouard Januel[SUP] 2 [/SUP], Pierre Labauge[SUP] 3 [/SUP], Elisabeth Maillart[SUP] 1 [/SUP], Jérôme de Seze[SUP] 4 [/SUP], Hélène Zéphir[SUP] 5 [/SUP], Jean Pelletier[SUP] 6 [/SUP], Philippe Kerschen[SUP] 7 [/SUP], Damien Biotti[SUP] 8 [/SUP], Olivier Heinzlef[SUP] 9 [/SUP], Laurent Guilloton[SUP] 10 [/SUP], Caroline Bensa[SUP] 11 [/SUP], Marie Théaudin[SUP] 12 [/SUP], Sandra Vukusic[SUP] 13 [/SUP], Olivier Casez[SUP] 14 [/SUP], Aude Maurousset[SUP] 15 [/SUP], David Laplaud[SUP] 16 [/SUP], Eric Berger[SUP] 17 [/SUP], Christine Lebrun-Frenay[SUP] 18 [/SUP], Bertrand Bourre[SUP] 19 [/SUP], Pierre Branger[SUP] 20 [/SUP], Bruno Stankoff[SUP] 21 [/SUP], Pierre Clavelou[SUP] 22 [/SUP], Eric Thouvenot[SUP] 23 [/SUP], Eric Manchon[SUP] 24 [/SUP], Thibault Moreau[SUP] 25 [/SUP], François Sellal[SUP] 26 [/SUP], Mickaël Zedet[SUP] 27 [/SUP], Caroline Papeix[SUP] 11 [/SUP], Céline Louapre[SUP] 1 [/SUP]
Affiliations
- PMID: 38247113
- DOI: 10.1177/13524585231218149
Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021.
Objectives: We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022.
Methods: This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity.
Results: Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave (p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25-1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51-2.67]), obesity (OR = 2.36, 95% CI = [1.52-3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46-3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43-3.06] for EDSS 3-5.5 and OR = 4.53, 95% CI = [3.04-6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85-3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60-0.69]) or off (RR = 0.32, 95% CI = [0.30-0.33]) anti-CD20.
Discussion: In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.
Keywords: COVID-19; COVID-19 testing; COVID-19 vaccines; Multiple sclerosis; SARS-CoV-2; vaccination.